AEON Biopharma, Inc. current report, 21 July 2023

Full document

AEON Biopharma, Inc. Form 8-K Summary

Business context and reporting period

AEON Biopharma, Inc. filed a current report covering events beginning July 21, 2023. The filing reports completion of the merger between Priveterra Acquisition Corp. and Old AEON Biopharma, with Priveterra changing its name to AEON Biopharma, Inc. AEON ceased to be a shell company and became the successor issuer. The filing also incorporates financial information for Old AEON for the three months ended March 31, 2023 and 2022, and for the years ended December 31, 2022 and 2021.

Key financial metrics, financing, and liquidity

  • Holders of 1,445,112 public shares exercised redemption rights at approximately $10.63 per share, representing approximately $21.29 million based on the stated redemption amount.
  • The filing also states that approximately $15.36 million was paid from the trust account and that approximately $5.92 million remained immediately before closing and was used to fund the Business Combination. The filing text does not clearly reconcile these two trust-account figures.
  • Investors converted $40.0 million of interim notes into 5,797,611 newly issued Class A common shares at closing.
  • Committed financing arrangements contemplated additional interim notes, including $15.0 million under the original Alphaeon subscription, $20.0 million of additional Alphaeon commitments, and $5.0 million of Daewoong commitments. The filing does not clearly state the total amount funded under each arrangement beyond the $40.0 million converted at closing.
  • New-money PIPE investors subscribed for 1,000,000 shares at $7.00 per share, generating stated gross proceeds of $7.0 million. An additional 75,000 shares were issued as a structuring fee.
  • After the Transactions, redemptions, and financing transactions, 37,154,198 shares of common stock were issued and outstanding.
  • The filing does not provide clear current-period revenue, net income or loss, operating cash flow, gross margin, operating margin, cash balance outside the trust-account disclosure, or total debt balances in the supplied text. Detailed financial statements and MD&A are incorporated by reference in Exhibits 99.1 through 99.3.

Material changes versus the prior comparable period

  • The company transitioned from a special purpose acquisition company to an operating biopharmaceutical company focused on ABP-450 and potential therapeutic indications.
  • Public trading changed from Priveterra securities to AEON common stock and warrants under the symbols AEON and AEON WS on the NYSE American beginning July 24, 2023, subject to continued listing review.
  • The company adopted a new board and executive leadership team. Marc Forth became Chief Executive Officer, Peter Reynolds became Chief Financial Officer, Chad Oh became Chief Medical Officer, and Alex Wilson became Executive Vice President, Chief Legal Officer and Corporate Secretary.
  • AEON adopted a 2023 Incentive Award Plan initially covering 3,839,892 shares, subject to additional annual increases, and a 2023 Employee Stock Purchase Plan initially covering 488,146 shares.
  • AEON adopted an amended and restated certificate of incorporation, amended and restated bylaws, and a new Code of Business Conduct and Ethics.
  • WithumSmith + Brown LLP was dismissed as the predecessor registrant’s independent auditor. The company was seeking a successor auditor for the year ending December 31, 2023. The filing reports no accounting disagreements or reportable events other than a previously disclosed material weakness.

Guidance, outlook, risks, contingencies, and unusual items

  • No formal revenue, earnings, cash runway, or product-commercialization guidance is provided in the filing text.
  • Management’s forward-looking statements address development and commercialization of ABP-450, regulatory approval and BLA prospects, clinical and preclinical programs, financing needs, intellectual property, market acceptance, manufacturing, competition, supply chain disruption, litigation, personnel retention, internal controls, and potential effects of COVID-19.
  • The forward purchase arrangements may involve up to 7,500,000 shares in aggregate and include reset-price, valuation, settlement, registration-failure, delisting, and early-termination provisions. These arrangements may create future dilution or cash/share settlement obligations.
  • Forward purchase sellers waived certain redemption rights, which could reduce redemptions and affect the capital structure and market perception of the transaction.
  • A sponsor letter agreement may require transfer of up to 400,000 additional shares to certain PIPE investors if transferred shares have a volume-weighted average price below $7.00.
  • AEON issued 125,000 shares to service providers, subject to a 12-month lockup.
  • Under his employment agreement, the CEO receives a $550,000 annual base salary and has a target annual bonus opportunity equal to 100% of base salary. The Chief Medical Officer receives a $425,000 annual base salary and has a target annual bonus opportunity equal to 40% of base salary. Both agreements provide specified severance benefits.
  • AEON has not paid dividends and currently expects to retain earnings, if any, for operations.

Most important facts for investors to verify

  1. Review Exhibits 99.1 through 99.3 for actual revenue, operating expenses, net loss, cash burn, cash balances, debt, liquidity, and going-concern or funding disclosures.
  2. Reconcile the stated $21.29 million redemption amount, approximately $15.36 million paid from the trust account, and approximately $5.92 million remaining balance.
  3. Confirm the amount and terms of interim-note financing actually funded and the resulting dilution from converted notes, PIPE shares, warrants, options, and incentive plans.
  4. Analyze the forward purchase agreements and sponsor make-whole provisions for potential future dilution, cash obligations, and price-reset exposure.
  5. Verify continued NYSE American listing status and the effectiveness of resale registration rights and registration statements.
  6. Assess ABP-450 clinical, regulatory, manufacturing, intellectual-property, and commercialization risks, including dependence on Daewoong and the company’s future financing requirements.
  7. Confirm appointment of a successor independent registered public accounting firm and remediation of the previously disclosed material weakness.